Pilot Study to evaluateThrombomodulin to Rule Out Giant Cell Arteritis (GCA) in Polymyalgia Rheumatica (PMR) Patients. (THROPIQ)

Key facts

Sponsor

Centre Hospitalier Universitaire Dijon

Intervention

Additional blood samples(biological)

Enrollment

78 target

Eligibility

50 years · All sexes

Timeline

2024 – 2027

Study locations (1)

• CHU Dijon Bourgogne, Dijon, France

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Giant cell arteritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07108387
  Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGNCT07084480
  Giant Cell Arteritis - Ways to Precision Medicine
  Wuerzburg University Hospital
• RECRUITINGNANCT07001059
  oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
  Hôpital NOVO
• RECRUITINGNCT06894602
  Association of Ultrasonographic Temporal Artery Lesions and Relapse in Patients With Giant Cell Arteritis
  University Hospital, Brest
• RECRUITINGNCT05749094
  Optic Nerve Sheath Ultrasound in Giant Cell Arteritis
  Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
• ACTIVE NOT RECRUITINGNCT05703763
  The Applanation Tonometry in GCA Pilot
  Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
• RECRUITINGPHASE2NCT06887062
  Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)
  University of Edinburgh
• RECRUITINGNCT06742671
  Performance of a Fast-track Pathway for Giant Cell Arteritis Diagnosis
  Groupe Hospitalier de la Rochelle Ré Aunis

See all trials for Giant cell arteritis →